Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.5
4.8
Journals
Antibiotics
Special Issues
Narrow-Spectrum Antibiotics: How Can They Help in the Fight against...
share announcement

Narrow-Spectrum Antibiotics: How Can They Help in the Fight against Antimicrobial Resistance and How Can We Get More of Them?

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: closed (30 May 2020) | Viewed by 23053

Special Issue Editor

Dr. Chantal M. Morel

E-Mail Website
Guest Editor
Faculty of Medicine, University of Geneva, Rue Michel-Servet 1, 1206 Geneva, Switzerland
Interests: health economics; infectious diseases; antimicrobial resistance; incentives; research and development; antibiotic stewardship; surveillance
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As guest editor I’d like to bring your attention to an upcoming issue devoted to issues surrounding the production and use of narrow spectrum antibiotics.

The intention of the special issue to do the following:

  • Define the qualities of narrow spectrums and the biological and epidemiological advantages that can be achieved in promoting their development and use over those with a broader spectrum of activity. 
  • Summarize our experience with existing narrow spectrums will be explored at the evolutionary and clinical level.
  • Explore the ways in which we can optimally encourage the necessary research and development of such products, looking across the variety of strategies, comparing the attributes of schemes required to bring them to market.
  • Examine the role of such products within stewardship policies and how we can optimize their use to prolong the efficacy of antibiotics overall.

We hope that you will find this issue of interest.

Dr. Chantal M. Morel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Antibiotics
  • Antimicrobial resistance
  • Narrow-spectrum
  • Research & Development
  • Health economics

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

14 pages, 4297 KiB  
Article
Synthesis of 4,4′-(4-Formyl-1H-pyrazole-1,3-diyl)dibenzoic Acid Derivatives as Narrow Spectrum Antibiotics for the Potential Treatment of Acinetobacter Baumannii Infections
by Evan Delancey, Devin Allison, Hansa Raj KC, David F. Gilmore, Todd Fite, Alexei G. Basnakian and Mohammad A. Alam
Antibiotics 2020, 9(10), 650; https://doi.org/10.3390/antibiotics9100650 - 28 Sep 2020
Cited by 13 | Viewed by 2704
Abstract
Acinetobacter baumannii has emerged as one of the most lethal drug-resistant bacteria in recent years. We report the synthesis and antimicrobial studies of 25 new pyrazole-derived hydrazones. Some of these molecules are potent and specific inhibitors of A. baumannii strains with a minimum [...] Read more.
Acinetobacter baumannii has emerged as one of the most lethal drug-resistant bacteria in recent years. We report the synthesis and antimicrobial studies of 25 new pyrazole-derived hydrazones. Some of these molecules are potent and specific inhibitors of A. baumannii strains with a minimum inhibitory concentration (MIC) value as low as 0.78 µg/mL. These compounds are non-toxic to mammalian cell lines in in vitro studies. Furthermore, one of the potent molecules has been studied for possible in vivo toxicity in the mouse model and found to be non-toxic based on the effect on 14 physiological blood markers of organ injury. Full article
(This article belongs to the Special Issue Narrow-Spectrum Antibiotics: How Can They Help in the Fight against Antimicrobial Resistance and How Can We Get More of Them?)
►▼ Show Figures

Figure 1

10 pages, 493 KiB  
Communication
Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and Thrive
by M. Courtney Safir, Sujata M. Bhavnani, Christine M. Slover, Paul G. Ambrose and Christopher M. Rubino
Antibiotics 2020, 9(7), 412; https://doi.org/10.3390/antibiotics9070412 - 15 Jul 2020
Cited by 12 | Viewed by 5185
Abstract
It is often said that the marketplace for new antibiotics is broken. This notion is supported by the observation that many recently-approved antibiotics to treat drug-resistant bacteria have failed commercially in a spectacular fashion. Today, companies with peak market-cap values in excess of [...] Read more.
It is often said that the marketplace for new antibiotics is broken. This notion is supported by the observation that many recently-approved antibiotics to treat drug-resistant bacteria have failed commercially in a spectacular fashion. Today, companies with peak market-cap values in excess of USD 500 million to 1 billion prior to product launch regularly sell for pennies on the dollar a few years after market introduction. It is possible, however, that the market is not as broken as we perceive. That is, in the collective mind of the clinician, recently-approved antibiotics may be too-poorly differentiated to justify their broad use and inordinate cost relative to those already existing. Perhaps we in the antibacterial drug development field must change our way of thinking if we are to survive and thrive. Rather than reflexively developing new β-lactam-β-lactamase inhibitor combinations for every new enzyme that evades our current inhibitors, we should focus discovery and development efforts on agents that revolutionize how we potentiate antibiotics. To this end, there has been renewed interest in phage therapies, virulence inhibitors, bacterial growth rate modulators, monoclonal antibodies, and other approaches to augment antibiotic effects. Herein, we suggest that the unmet medical need is less about adding poorly-differentiated antibiotics to our armamentarium and more about the need for innovation in how we augment antibiotic regimen effects. Full article
(This article belongs to the Special Issue Narrow-Spectrum Antibiotics: How Can They Help in the Fight against Antimicrobial Resistance and How Can We Get More of Them?)
►▼ Show Figures

Figure 1

14 pages, 4913 KiB  
Article
Antimicrobial and Antifungal Activity of Rare Substituted 1,2,3-Thiaselenazoles and Corresponding Matched Pair 1,2,3-Dithiazoles
by Tuomo Laitinen, Ilia V. Baranovsky, Lidia S. Konstantinova, Antti Poso, Oleg A. Rakitin and Christopher R. M. Asquith
Antibiotics 2020, 9(7), 369; https://doi.org/10.3390/antibiotics9070369 - 1 Jul 2020
Cited by 9 | Viewed by 3401
Abstract
We report our investigations into the underlying differences between 1,2,3-dithiazole and their ultra-rare counterpart, 1,2,3-thiaselenazole. This rare 1,2,3-thiaselenazole chemotype was afforded by sulfur extrusion and selenium insertion into the preconstructed 1,2,3-dithiazoles. We built a library of matched paired compounds to compare and contrast [...] Read more.
We report our investigations into the underlying differences between 1,2,3-dithiazole and their ultra-rare counterpart, 1,2,3-thiaselenazole. This rare 1,2,3-thiaselenazole chemotype was afforded by sulfur extrusion and selenium insertion into the preconstructed 1,2,3-dithiazoles. We built a library of matched paired compounds to compare and contrast the two ring systems. This led to the development of both narrow and broad-spectrum antimicrobial compounds with sub-micro molar potency, limited to no toxicity and a further understanding of the transition state electronics through molecular simulations. We also identified the potent 4,5,6-trichlorocyclopenta[d][1,2,3]thiaselenazole 11a, for use against Candida albicans, Cryptococcus neoformans var. grubii, Staphylococcus aureus and Acinetobacter baumannii, all of which have limited clinical treatment options. The 1,2,3-thiaselenazole represents a new class of potential compounds for the treatment of a host of multi-resistant hospital derived infections. Full article
(This article belongs to the Special Issue Narrow-Spectrum Antibiotics: How Can They Help in the Fight against Antimicrobial Resistance and How Can We Get More of Them?)
►▼ Show Figures

Graphical abstract

Other

Jump to: Research

13 pages, 1133 KiB  
Perspective
In the Age of Synthetic Biology, Will Antimicrobial Peptides be the Next Generation of Antibiotics?
by Félix Jaumaux, Luz P. Gómez de Cadiñanos and Philippe Gabant
Antibiotics 2020, 9(8), 484; https://doi.org/10.3390/antibiotics9080484 - 6 Aug 2020
Cited by 13 | Viewed by 4817
Abstract
Antibiotics have changed human health and revolutionised medical practice since the Second World War. Today, the use of antibiotics is increasingly limited by the rise of antimicrobial-resistant strains. Additionally, broad-spectrum antibiotic activity is not adapted to maintaining a balanced microbiome essential for human [...] Read more.
Antibiotics have changed human health and revolutionised medical practice since the Second World War. Today, the use of antibiotics is increasingly limited by the rise of antimicrobial-resistant strains. Additionally, broad-spectrum antibiotic activity is not adapted to maintaining a balanced microbiome essential for human health. Targeted antimicrobials could overcome these two drawbacks. Although the rational design of targeted antimicrobial molecules presents a formidable challenge, in nature, targeted genetically encoded killing molecules are used by microbes in their natural ecosystems. The use of a synthetic biology approach allows the harnessing of these natural functions. In this commentary article we illustrate the potential of applying synthetic biology towards bacteriocins to design a new generation of antimicrobials. Full article
(This article belongs to the Special Issue Narrow-Spectrum Antibiotics: How Can They Help in the Fight against Antimicrobial Resistance and How Can We Get More of Them?)
►▼ Show Figures

Figure 1

8 pages, 198 KiB  
Commentary
Narrow-Spectrum Antibacterial Agents—Benefits and Challenges
by Richard A. Alm and Sushmita D. Lahiri
Antibiotics 2020, 9(7), 418; https://doi.org/10.3390/antibiotics9070418 - 17 Jul 2020
Cited by 26 | Viewed by 6224
Abstract
The number of antibacterial agents in clinical and preclinical development possessing activity against a narrow spectrum of bacterial pathogens is increasing, with many of them being nontraditional products. The key value proposition hinges on sparing antibiotic use and curtailing the emergence of resistance, [...] Read more.
The number of antibacterial agents in clinical and preclinical development possessing activity against a narrow spectrum of bacterial pathogens is increasing, with many of them being nontraditional products. The key value proposition hinges on sparing antibiotic use and curtailing the emergence of resistance, as well as preventing the destruction of a beneficial microbiome, versus the immediate need for effective treatment of an active infection with a high risk of mortality. The clinical use of a targeted spectrum agent, most likely in combination with a rapid and robust diagnostic test, is a commendable goal with significant healthcare benefits if executed correctly. However, the path to achieving this will come with several challenges, and many scientific and clinical development disciplines will need to align their efforts to successfully change the treatment paradigm. Full article
(This article belongs to the Special Issue Narrow-Spectrum Antibiotics: How Can They Help in the Fight against Antimicrobial Resistance and How Can We Get More of Them?)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop